Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 91Thoracic 10CNS 8Sarcoma 7Other solid neoplasm 7Tumor-Agnostic 6Head & Neck 4Gynecologic 4Breast 4Endocrine 2NET 1Genitourinary 1

Conditions

Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × irinotecan sucrosofate × Endocrine × Clear all
NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed
58 enrolled
Endocrine

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡